The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) alpha-308 G/G promoter polymorphism

Soto L.; Sabugo, F; Catalan D.; Wurmann, P; Cermenatti T.; Gatica H.; Aravena, O; Salazar, L; Aguillón JC; Cuchacovich M.

Más información

Título según WOS: The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) alpha-308 G/G promoter polymorphism
Título según SCOPUS: The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) ?-308 G/G promoter polymorphism
Título de la Revista: Clinical Rheumatology
Volumen: 30
Asunto: 3
Editorial: Springer London
Fecha de publicación: 2011-01-01
Página de inicio: 391
Página final: 395
Idioma: English
DOI/URL:

10.1007/s10067-011-1679-4

Identificador: 10.1007/s10067-011-1679-4
Notas: ISI, SCOPUS